SurModics (NASDAQ: SRDX) reported Q3 EPS of $0.26, $0.05 better than the analyst estimate of $0.21. Revenue for the quarter came in at $15.9 million versus the consensus estimate of $14.86 million.

According to SurModics’ President and Chief Executive Officer Gary Maharaj, “SurModics delivered solid revenue and earnings gains for quarter. Both of our segments contributed, with the In Vitro Diagnostics business continuing its strong growth trajectory with a 13% revenue increase. Even while advancing our drug coated balloon program, non-GAAP operating margins reached 34%.”

For earnings history and earnings-related data on SurModics (SRDX) click here.